These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38806289)

  • 21. Cetuximab or nimotuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy for stage II-IVb nasopharyngeal carcinoma.
    You R; Sun R; Hua YJ; Li CF; Li JB; Zou X; Yang Q; Liu YP; Zhang YN; Yu T; Cao JY; Zhang MX; Jiang R; Mo HY; Guo L; Cao KJ; Lin AH; Qian CN; Sun Y; Ma J; Chen MY
    Int J Cancer; 2017 Sep; 141(6):1265-1276. PubMed ID: 28577306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term results of a phase II study of gemcitabine and cisplatin chemotherapy combined with intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma.
    Wu M; Ou D; He X; Hu C
    Oral Oncol; 2017 Oct; 73():118-123. PubMed ID: 28939063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A retrospective paired study: efficacy and toxicity of nimotuzumab versus cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma.
    Li HM; Li P; Qian YJ; Wu X; Xie L; Wang F; Zhang H; Liu L
    BMC Cancer; 2016 Dec; 16(1):946. PubMed ID: 27955638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intensity-modulated radiotherapy alone compared with intensity-modulated radiotherapy plus concurrent chemotherapy in intermediate-risk nasopharyngeal carcinoma : A prospective multicenter phase II trial.
    Liao S; Zhang B; Su Y; Pan Y; Zhang J; Ye Z; Zhang R; Kong X; Qin G; Mo Y; Ruan X; Liu J; Gan C; Dai J; Zhang R; Luo G; Liao X; Jiang W
    Strahlenther Onkol; 2024 Oct; 200(10):867-875. PubMed ID: 38324078
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma.
    Ma BBY; Kam MKM; Leung SF; Hui EP; King AD; Chan SL; Mo F; Loong H; Yu BKH; Ahuja A; Chan ATC
    Ann Oncol; 2012 May; 23(5):1287-1292. PubMed ID: 21948811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus neoadjuvant chemotherapy plus concurrent chemoradiotherapy for ascending or descending types of nasopharyngeal carcinoma: A retrospective study.
    Lin Q; Lu L; Wang X; Lin Y; Chen Y; Chen H; Chen S; Lin S; Zhang Y; Zheng P; Chen X
    Am J Otolaryngol; 2022; 43(1):103193. PubMed ID: 34509080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma.
    Wu S; Quan R; Han L; Zhang H; Zhang B; Xu G; Li X
    Medicine (Baltimore); 2020 Jul; 99(30):e21325. PubMed ID: 32791728
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a retrospective analysis.
    Liu ZG; Zhao Y; Tang J; Zhou YJ; Yang WJ; Qiu YF; Wang H
    Oncotarget; 2016 Apr; 7(17):24429-35. PubMed ID: 27016412
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radiotherapy alone versus concurrent chemoradiotherapy in patients with stage II and T3N0 nasopharyngeal carcinoma with adverse features: A propensity score-matched cohort study.
    Zhang WW; Lin JY; Wang GY; Huang CL; Tang LL; Mao YP; Zhou GQ; Liu LZ; Tian L; Li JB; Ma J; Guo R
    Radiother Oncol; 2024 May; 194():110189. PubMed ID: 38432309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction plus adjuvant chemotherapy, combined treatment with nimotuzumab, and intensity-modulated radiation therapy for N3 stage nasopharyngeal carcinoma: A pilot study.
    Zhou L; Lin J; Chen J; Zhang S
    J Cancer Res Ther; 2021 Dec; 17(7):1730-1735. PubMed ID: 35381746
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness and cost-effectiveness analysis of nimotuzumab for the radiotherapy of locoregionally advanced nasopharyngeal carcinoma.
    Fei Z; Xu T; Li M; Chen T; Li L; Qiu X; Chen C
    Radiat Oncol; 2020 Oct; 15(1):230. PubMed ID: 33008416
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus volumetric modulated arc therapy alone in the treatment of stage II-IVB nasopharyngeal carcinoma patients: a retrospective controlled study.
    Liu L; Fei Z; Chen M; Zhao L; Su H; Gu D; Lin B; Cai X; Lu L; Gao M; Ye X; Jin X; Xie C
    Radiat Oncol; 2018 Aug; 13(1):148. PubMed ID: 30103765
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intensity-modulated radiotherapy combined with endostar has similar efficacy but weaker acute adverse reactions than IMRT combined with chemotherapy in the treatment of locally advanced nasopharyngeal carcinoma.
    Kang M; Wang F; Liao X; Zhou P; Wang R
    Medicine (Baltimore); 2018 Jun; 97(25):e11118. PubMed ID: 29924009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical outcome of intensity-modulated radiotherapy versus two-dimensional conventional radiotherapy in locally advanced nasopharyngeal carcinoma: Comparative study at SKIMS Tertiary Care Institute.
    Fatima K; Andleeb A; Sofi MA; Rasool MT; Fir A; Nasreen S; Dar NA
    J Cancer Res Ther; 2022; 18(1):133-139. PubMed ID: 35381774
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An open-label, single-arm phase II clinical study of induction chemotherapy and sequential Nimotuzumab combined with concurrent chemoradiotherapy in N3M0 stage nasopharyngeal carcinoma.
    Zhang S; Huang X; Zhou L; Wu G; Lin J; Yang S; Chen J; Lin S
    J BUON; 2018; 23(6):1656-1661. PubMed ID: 30610791
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: treatment outcomes of a prospective, multicentric clinical study.
    Wu F; Wang R; Lu H; Wei B; Feng G; Li G; Liu M; Yan H; Zhu J; Zhang Y; Hu K
    Radiother Oncol; 2014 Jul; 112(1):106-11. PubMed ID: 24933452
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mixed-beam approach in locally advanced nasopharyngeal carcinoma: IMRT followed by proton therapy boost versus IMRT-only. Evaluation of toxicity and efficacy.
    Alterio D; D'Ippolito E; Vischioni B; Fossati P; Gandini S; Bonora M; Ronchi S; Vitolo V; Mastella E; Magro G; Franco P; Ricardi U; Krengli M; Ivaldi G; Ferrari A; Fanetti G; Comi S; Tagliabue M; Verri E; Ricotti R; Ciardo D; Jereczek-Fossa BA; Valvo F; Orecchia R
    Acta Oncol; 2020 May; 59(5):541-548. PubMed ID: 32090645
    [No Abstract]   [Full Text] [Related]  

  • 38. Diffusion-Weighted Magnetic Resonance Imaging-Guided Dose Painting in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Treated With Induction Chemotherapy Plus Concurrent Chemoradiotherapy: A Randomized, Controlled Clinical Trial.
    Fu S; Li Y; Han Y; Wang H; Chen Y; Yan O; He Q; Ma H; Liu L; Liu F
    Int J Radiat Oncol Biol Phys; 2022 May; 113(1):101-113. PubMed ID: 35074433
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic factors of 305 nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy.
    Han L; Lin SJ; Pan JJ; Chen CB; Zhang Y; Zhang XC; Liao XY; Chen QS
    Chin J Cancer; 2010 Feb; 29(2):145-50. PubMed ID: 20109341
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Necessity of concurrent chemotherapy in N2-3 nasopharyngeal carcinoma treated with neoadjuvant chemotherapy of ≥3 cycles followed by intensity-modulated radiotherapy.
    Chang H; Peng L; Tao YL; Chen C; Xiao WW; Hu YH; Gao YH
    Cancer Med; 2019 Jun; 8(6):2823-2831. PubMed ID: 31006996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.